Russell Pachynski

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Castration 69%
3. Immunotherapy 59%
4. Renal Cell Carcinoma 54%
5. Neoplasms 53%
6. Nivolumab 45%
7. T-Lymphocytes 35%
8. sipuleucel-T 34%
9. Natural Killer Cells 31%
10. Leukocytes 28%
11. Urinary Bladder Neoplasms 25%
12. Survival 24%
13. Tumor Microenvironment 24%
14. Cell Adhesion Molecule-1 24%
15. Therapeutics 23%
16. Integrins 23%
17. Multiparametric Magnetic Resonance Imaging 22%
18. Anti-Idiotypic Antibodies 20%
19. Antigens 19%
20. rucaparib 16%
21. Chemotactic Factors 16%
22. Safety 16%
23. Proteogenomics 16%
24. TRC105 16%
25. pazopanib 16%
26. Ipilimumab 15%
27. Melanoma 15%
28. Radiotherapy 15%
29. Proteomics 14%
30. Drug Therapy 14%
31. Carcinoma 13%
32. Inducible T-Cell Co-Stimulator Protein 13%
33. Chemokine CCL21 13%
34. cabozantinib 13%
35. Neoplasm Metastasis 12%
36. Progression-Free Survival 12%
37. Lymphocytes 12%
38. Axitinib 12%
39. Central Tolerance 12%
40. CSK Tyrosine-Protein Kinase 12%
41. Docetaxel 11%
42. Chemokines 11%
43. Noise 11%
44. Melanoma-Specific Antigens 11%
45. Dendritic Cells 11%
46. Biomarkers 11%
47. Histology 10%
48. Interleukin-7 10%
49. Cell-Free Nucleic Acids 10%
50. tazarotene 10%